2. Until specific recommendations are validated for endocervical adenocarcinoma, prediction of immunotherapy response criteria is identical to that for squamous cervical cancer. At present, PD-L1 immunohistochemistry (CPS of 1 or higher), as determined by the FDA approved companion test, by 22C3 clone, is recommended for pembrolizumab treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This evidence concerns the gene CD274 and endocervical adenocarcinoma.